Faculty of Medicine and Health Sciences, University of Malaysia Sarawak(UNIMAS), Jalan Dato Muhammad Musa, 94300, Kota Samarahan, Sarawak, Malaysia.
Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
BMC Psychiatry. 2019 Jan 8;19(1):12. doi: 10.1186/s12888-018-2006-2.
Although depression is associated with changes in the hypothalamic-pituitary-thyroid axis, its relationship with subclinical hypothyroidism (SCH) is controversial. To date, there is a lack of data on the improvement of depressive symptoms with levothyroxine therapy among individuals with coexistent SCH.
We conducted a meta-analysis to evaluate the association between SCH and depression including 1) the prevalence of depression in SCH (with a sub-analysis of the geriatric cohort), 2) thyroid stimulating hormone (TSH) level among patients with depression and 3) the effect of levothyroxine therapy among patients with SCH and coexistent depression.
In a pooled analysis of 12,315 individuals, those with SCH had higher risk of depression than euthyroid controls (relative risk 2.35, 95% confidence intervals [CI], 1.84 to 3.02; p < 0.001). Geriatric cohort with SCH had a 1.7-fold higher risk of depression compared with healthy controls (odds ratio 1.72, CI, 1.10 to 2.70; p = 0.020). There was no difference in the mean TSH level between individuals with depression and healthy controls (2.30 ± 1.18 vs. 2.13 ± 0.72 mIU/L, p = 0.513). In individuals with SCH and coexistent depression, levothyroxine therapy was neither associated with improvement in the Beck Depression Inventory scoring (pooled d + = - 1.05, CI -2.72 to 0.61; p = 0.215) nor Hamilton Depression Rating Scale (pooled d + = - 2.38, CI -4.86 to 0.10; p = 0.060).
SCH has a negative impact on depression. Early and routine screening of depression is essential to prevent morbidity and mortality. However, the use of levothyroxine among patients with SCH and coexistent depression needs to be individualized.
尽管抑郁症与下丘脑-垂体-甲状腺轴的变化有关,但它与亚临床甲状腺功能减退症(SCH)的关系仍存在争议。迄今为止,关于同时患有 SCH 的个体接受左甲状腺素治疗后抑郁症状改善的数据尚缺乏。
我们进行了一项荟萃分析,以评估 SCH 与抑郁症之间的关系,包括 1)SCH 患者中抑郁症的患病率(对老年队列进行亚分析),2)抑郁症患者的促甲状腺激素(TSH)水平,以及 3)SCH 合并抑郁症患者接受左甲状腺素治疗的效果。
在对 12315 人的汇总分析中,SCH 患者患抑郁症的风险高于甲状腺功能正常的对照组(相对风险 2.35,95%置信区间[CI],1.84 至 3.02;p<0.001)。患有 SCH 的老年队列与健康对照组相比,患抑郁症的风险高 1.7 倍(优势比 1.72,CI,1.10 至 2.70;p=0.020)。抑郁症患者与健康对照组之间的平均 TSH 水平无差异(2.30±1.18 与 2.13±0.72 mIU/L,p=0.513)。在同时患有 SCH 和抑郁症的个体中,左甲状腺素治疗既不能改善贝克抑郁量表评分(汇总 d+=−1.05,CI−2.72 至 0.61;p=0.215),也不能改善汉密尔顿抑郁评定量表评分(汇总 d+=−2.38,CI−4.86 至 0.10;p=0.060)。
SCH 对抑郁症有负面影响。早期和常规筛查抑郁症对于预防发病率和死亡率至关重要。然而,SCH 合并抑郁症患者使用左甲状腺素需要个体化。